DOI: 10.1097/icb.0000000000001468 ISSN:

Subretinal fluid associated with pemigatinib therapy for cholangiocarcinoma; a case report and literature review Pemigatinib-associated subretinal fluid

Jonathan T. Caranfa, Phoebe Mellen, Michelle C. Liang
  • Ophthalmology
  • General Medicine



To describe the retinal findings associated with pemigatinib, an oral competitive inhibitor of fibroblast growth factor receptor (FGFR) approved for the treatment of cholangiocarcinoma.


We present a case report and performed a literature review, revealing only two prior reported cases of pemigatinib-mediated subretinal fluid.


A 72-year-old woman presented with transient visual symptoms while on pemigatinib for the treatment of cholangiocarcinoma. Optical coherence tomography (OCT) revealed subfoveal subretinal fluid bilaterally that resolved during a drug holiday, however fluctuated throughout her treatment course. She remained on pemigatinib for ten months without other ocular sequelae.


This is one of the few reported cases of pemigatinib-related retinopathy, which further supports the self-limited and benign nature of subretinal fluid associated with FGFR inhibitors.

More from our Archive